NASDAQ:CBAY CymaBay Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.80 -0.04 (-1.41%) (As of 06/28/2022 11:52 AM ET) Add Compare Share Today's Range$2.69▼$2.9050-Day Range$1.72▼$3.0052-Week Range$1.67▼$4.79Volume22,140 shsAverage Volume1.12 million shsMarket Capitalization$237.10 millionP/E RatioN/ADividend YieldN/APrice Target$10.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CBAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CBAY Stock Forecast (MarketRank)Overall MarketRank™2.38 out of 5 starsMedical Sector207th out of 1,436 stocksPharmaceutical Preparations Industry84th out of 687 stocksAnalyst Opinion: 3.6Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 - 3.6 Analyst's Opinion Consensus RatingCymaBay Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.80, CymaBay Therapeutics has a forecasted upside of 280.3% from its current price of $2.84.Amount of Analyst CoverageCymaBay Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.9 Community Rank Outperform VotesCymaBay Therapeutics has received 479 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCymaBay Therapeutics has received 173 “underperform” votes. (Add your “underperform” vote.)Community SentimentCymaBay Therapeutics has received 73.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CymaBay Therapeutics and other stocks. Vote “Outperform” if you believe CBAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBAY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCymaBay Therapeutics does not currently pay a dividend.Dividend GrowthCymaBay Therapeutics does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CymaBay Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,037.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of CymaBay Therapeutics is held by insiders.Percentage Held by Institutions78.34% of the stock of CymaBay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CymaBay Therapeutics are expected to decrease in the coming year, from ($1.23) to ($1.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CymaBay Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CymaBay Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCymaBay Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CymaBay Therapeutics (NASDAQ:CBAY)CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.Read More CBAY Stock News HeadlinesJune 27, 2022 | seekingalpha.comCymaBay: Long-Term Potential Based On Prior PBC Trial ResultsJune 27, 2022 | americanbankingnews.comCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Receives $10.80 Consensus Price Target from BrokeragesJune 22, 2022 | marketwatch.comCymaBay Therapeutics Shares Rise 7% After Positive Data for Seladelpar TrialJune 22, 2022 | finance.yahoo.comCymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022June 9, 2022 | finance.yahoo.comTrade Alert: The President Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Sujal Shah, Has Just Spent US$100k Buying 43% More SharesJune 9, 2022 | americanbankingnews.comCymaBay Therapeutics, Inc. Forecasted to Earn FY2023 Earnings of ($1.45) Per Share (NASDAQ:CBAY)June 8, 2022 | finance.yahoo.comCymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022May 23, 2022 | seekingalpha.comCymaBay announces result from two-year study of primary biliary cholangitis therapyMay 23, 2022 | finance.yahoo.comCymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free SurvivalMay 23, 2022 | finance.yahoo.comCymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free SurvivalMay 16, 2022 | seekingalpha.comCymaBay price target lowered at H.C. Wainwright on enrollment delay for key studyMay 13, 2022 | benzinga.comCymaBay Therapeutics: Q1 Earnings InsightsMay 13, 2022 | seekingalpha.comCymaBay Therapeutics GAAP EPS of -$0.32 misses by $0.01See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBAY CUSIPN/A CIK1042074 Webwww.cymabay.com Phone(510) 293-8800Fax510-293-9090Employees59Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/28/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$10.80 High Stock Price Forecast$14.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+285.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.330010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90 million Net MarginsN/A Pretax MarginN/A Return on Equity-92.26% Return on Assets-62.35% Debt Debt-to-Equity Ratio0.73 Current Ratio13.68 Quick Ratio13.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.93 per share Price / Book1.45Miscellaneous Outstanding Shares84,680,000Free Float80,021,000Market Cap$237.10 million OptionableOptionable Beta1.09 CymaBay Therapeutics Frequently Asked Questions Should I buy or sell CymaBay Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CymaBay Therapeutics stock. View analyst ratings for CymaBay Therapeutics or view top-rated stocks. What is CymaBay Therapeutics' stock price forecast for 2022? 4 equities research analysts have issued 12-month price targets for CymaBay Therapeutics' stock. Their CBAY stock forecasts range from $8.00 to $14.00. On average, they expect CymaBay Therapeutics' stock price to reach $10.80 in the next twelve months. This suggests a possible upside of 285.7% from the stock's current price. View analysts' price targets for CymaBay Therapeutics or view top-rated stocks among Wall Street analysts. How has CymaBay Therapeutics' stock performed in 2022? CymaBay Therapeutics' stock was trading at $3.38 on January 1st, 2022. Since then, CBAY shares have decreased by 17.2% and is now trading at $2.80. View the best growth stocks for 2022 here. When is CymaBay Therapeutics' next earnings date? CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for CymaBay Therapeutics. How were CymaBay Therapeutics' earnings last quarter? CymaBay Therapeutics, Inc. (NASDAQ:CBAY) announced its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.01. During the same period in the previous year, the firm earned ($0.25) earnings per share. View CymaBay Therapeutics' earnings history. Who are CymaBay Therapeutics' key executives? CymaBay Therapeutics' management team includes the following people: Mr. Sujal A. Shah, Pres, CEO & Director (Age 49, Pay $873.87k)Dr. Dennis D. Kim M.B.A., M.D., MBA, Chief Medical Officer (Age 52, Pay $406.11k)Mr. Lewis J. Stuart B.A., BA, M.B.A., MBA, Chief Commercial Officer (Age 63, Pay $378.79k)Mr. Daniel Menold, VP of Fin. (Age 52)Dr. Charles A. McWherter Ph.D., Sr. VP & Chief Scientific Officer (Age 67)Mr. Paul T. Quinlan, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 59)Mr. Ken Boehm, Sr. VP of HRMr. Patrick J. O'Mara, Sr. VP of Bus. Devel. (Age 61)Dr. Robert L. Martin, Sr. VP of Manufacturing & Nonclinical Devel. (Age 60)Ms. Klara A. Dickinson-Eason, Chief Regulatory & Quality Assurance Officer (Age 54) Who are some of CymaBay Therapeutics' key competitors? Some companies that are related to CymaBay Therapeutics include Veru (VERU), Merus (MRUS), I-Mab (IMAB), Enanta Pharmaceuticals (ENTA), Deciphera Pharmaceuticals (DCPH), uniQure (QURE), Rocket Pharmaceuticals (RCKT), ADVANZ PHARMA (CXRXF), Morphic (MORF), Belite Bio (BLTE), IGM Biosciences (IGMS), Design Therapeutics (DSGN), Phibro Animal Health (PAHC), Verve Therapeutics (VERV) and Nuvation Bio (NUVB). View all of CBAY's competitors. What other stocks do shareholders of CymaBay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX). What is CymaBay Therapeutics' stock symbol? CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY." Who are CymaBay Therapeutics' major shareholders? CymaBay Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.46%), Vanguard Group Inc. (4.54%), Nantahala Capital Management LLC (2.24%), State Street Corp (1.60%), JPMorgan Chase & Co. (1.54%) and Affinity Asset Advisors LLC (1.50%). Company insiders that own CymaBay Therapeutics stock include Dennis D Kim and Sujal Shah. View institutional ownership trends for CymaBay Therapeutics. Which major investors are selling CymaBay Therapeutics stock? CBAY stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Nantahala Capital Management LLC, JPMorgan Chase & Co., Prosight Management LP, Invesco Ltd., GSA Capital Partners LLP, UBS Group AG, and ClariVest Asset Management LLC. View insider buying and selling activity for CymaBay Therapeutics or view top insider-selling stocks. Which major investors are buying CymaBay Therapeutics stock? CBAY stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Affinity Asset Advisors LLC, Dimensional Fund Advisors LP, BlackRock Inc., Goldman Sachs Group Inc., Northern Trust Corp, Connor Clark & Lunn Investment Management Ltd., and Charles Schwab Investment Management Inc.. Company insiders that have bought CymaBay Therapeutics stock in the last two years include Dennis D Kim, and Sujal Shah. View insider buying and selling activity for CymaBay Therapeutics or or view top insider-buying stocks. How do I buy shares of CymaBay Therapeutics? Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CymaBay Therapeutics' stock price today? One share of CBAY stock can currently be purchased for approximately $2.80. How much money does CymaBay Therapeutics make? CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $237.10 million. The biopharmaceutical company earns $-90 million in net income (profit) each year or ($1.330010) on an earnings per share basis. How many employees does CymaBay Therapeutics have? CymaBay Therapeutics employs 59 workers across the globe. How can I contact CymaBay Therapeutics? CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for CymaBay Therapeutics is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at [email protected], or via fax at 510-293-9090. This page (NASDAQ:CBAY) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
